Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -26,602 | -40,674 | -50,733 | -53,010 | -44,161 |
| Depreciation Amortization | 783 | 434 | 359 | 632 | 1,253 |
| Accounts receivable | -4,601 | 753 | -1,641 | 3,085 | -1,725 |
| Other Working Capital | -723 | -2,938 | -934 | 356 | -4,388 |
| Other Operating Activity | 9,456 | 6,096 | 12,988 | 7,131 | 10,183 |
| Operating Cash Flow | $-21,687 | $-36,329 | $-39,961 | $-41,806 | $-38,837 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 16,500 | N/A | 25,000 | -24,445 | 10,000 |
| PPE Investments | -137 | 32 | 2 | -165 | -892 |
| Purchase Of Investment | -16,288 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $75 | $32 | $25,002 | $-24,610 | $9,109 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 10,000 | N/A |
| Common Stock Issued | 28,289 | 10,831 | 473 | 22,702 | 2,599 |
| Other Financing Activity | -1,998 | -588 | 11,387 | 20,957 | 16,635 |
| Financing Cash Flow | $26,291 | $10,243 | $11,860 | $53,659 | $19,233 |
| Beginning Cash Position | 22,611 | 48,665 | 51,764 | 64,521 | 75,016 |
| End Cash Position | 27,290 | 22,611 | 48,665 | 51,764 | 64,521 |
| Net Cash Flow | $4,679 | $-26,054 | $-3,099 | $-12,757 | $-10,495 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,687 | -36,329 | -39,961 | -41,806 | -38,837 |
| Capital Expenditure | -177 | -66 | N/A | -171 | -913 |
| Free Cash Flow | -21,864 | -36,395 | -39,961 | -41,977 | -39,750 |